- Home
- CAAS vs IPHA Comparison
CAAS vs IPHA Comparison
Compare CAAS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAS
- IPHA
- Stock Information
- Founded
- CAAS N/A
- IPHA 1999
- Country
- CAAS China
- IPHA France
- Employees
- CAAS N/A
- IPHA N/A
- Industry
- CAAS Auto Parts:O.E.M.
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CAAS Consumer Discretionary
- IPHA Health Care
- Exchange
- CAAS Nasdaq
- IPHA Nasdaq
- Market Cap
- CAAS 148.1M
- IPHA 160.1M
- IPO Year
- CAAS N/A
- IPHA 2019
- Fundamental
- Price
- CAAS $4.37
- IPHA $2.02
- Analyst Decision
- CAAS
- IPHA Hold
- Analyst Count
- CAAS 0
- IPHA 2
- Target Price
- CAAS N/A
- IPHA $2.00
- AVG Volume (30 Days)
- CAAS 56.2K
- IPHA 20.0K
- Earning Date
- CAAS 11-12-2025
- IPHA 09-17-2025
- Dividend Yield
- CAAS N/A
- IPHA N/A
- EPS Growth
- CAAS N/A
- IPHA N/A
- EPS
- CAAS 0.97
- IPHA N/A
- Revenue
- CAAS $696,272,000.00
- IPHA $14,839,695.00
- Revenue This Year
- CAAS N/A
- IPHA $350.96
- Revenue Next Year
- CAAS N/A
- IPHA $32.92
- P/E Ratio
- CAAS $4.61
- IPHA N/A
- Revenue Growth
- CAAS 17.08
- IPHA N/A
- 52 Week Low
- CAAS $3.50
- IPHA $1.29
- 52 Week High
- CAAS $5.37
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CAAS 39.70
- IPHA 53.75
- Support Level
- CAAS $4.57
- IPHA $1.95
- Resistance Level
- CAAS $4.69
- IPHA $2.10
- Average True Range (ATR)
- CAAS 0.15
- IPHA 0.06
- MACD
- CAAS -0.07
- IPHA 0.02
- Stochastic Oscillator
- CAAS 0.24
- IPHA 78.14
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.